Unraveling the genetic blueprint of doxorubicin-induced cardiotoxicity through systems genetics approaches
Survival, BW loss, and echocardiography parameters considerably varied among DOX-treated BXDs, suggesting significant influence of genetic background on expression of those traits. Several candidate genes that may modulate ACT susceptibility and heart failure were identified, providing a foundation for genetic-based risk stratification and therapeutics in cardio-oncology.
Authors
- Akhilesh Kumar Bajpai (ORCID: https://orcid.org/0000-0001-9023-1790)
- Buyan‐Ochir Orgil (ORCID: https://orcid.org/0000-0001-7932-2237)
- Neely R. Alberson
- Enkhsaikhan Purevjav (ORCID: https://orcid.org/0000-0001-6188-7176)
- Hugo R. Martinez (ORCID: https://orcid.org/0000-0002-3655-7930)
- Jeffrey A. Towbin (ORCID: https://orcid.org/0000-0002-4182-2786)
- Lu Lu (ORCID: https://orcid.org/0000-0002-9771-0206)
- Morgan Lander
- Batsaikhan Enkhzul
Institutions
- University of Tennessee Health Science Center (US)
- Le Bonheur Children's Hospital (US)
- The University of Texas at Austin (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1186/s40959-025-00349-y
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39